Clinical Setbacks of IGF1R Antibodies: From Figitumumab Monotherapy to a Combination-Treatment Paradigm Shift
After figitumumab monotherapy failed, the IGF1R antibody field shifted toward combination treatment and biomarker stratification. This article traces the paradigm shift in IGF1R translational research and its in vitro tool support.
- Recent Advances
- Product Information
Keywords: IGF1R antibodies, figitumumab, ganitumab, combination therapy, biomarkers, tumor targeting, UA016082, alpha2beta2
Note: The full article is published in Chinese. Please refer to the Chinese version for complete experimental details, figures and product references. For product inquiries, visit www.ua-bio.com.
This article is reviewed and published by the technical expert team of UA
Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.
Purchase recombinant protein, choose Nanjing UA-Bio
UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.
Business license (three certificates in one) 
